<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://articlefeeds.nasdaq.com/~d/styles/itemcontent.css"?><rss xmlns:a10="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel xmlns:nasdaq="http://nasdaq.com/reference/feeds/1.0/">
    <title>Latest Articles about CVD</title>
    <description />
    <language>EN-US</language>
    <lastBuildDate>Tue, 18 Jun 2013 18:44:35 -0400</lastBuildDate>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://articlefeeds.nasdaq.com/nasdaq/symbols?symbol=CVD" /><feedburner:info uri="nasdaq/symbols" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item xml:base="http://www.nasdaq.com/article/omnicare-unit-partners-drug-buster-analyst-blog-cm249748">
      <guid isPermaLink="false">249748</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/avNPHHLRZCg/omnicare-unit-partners-drug-buster-analyst-blog-cm249748</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Omnicare Unit Partners Drug Buster - Analyst Blog</title>
      <description>Provider of drugs to long-term care facilities and nursing homes,  Omnicare Inc.  (  OCR  ) recently reported that Hospice Pharmacia, an offering of excelleRx Inc., an Omnicare Company, has&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/avNPHHLRZCg" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 30 May 2013 22:28:04 Z</pubDate>
      <a10:updated>2013-05-30T19:31:14Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>CYBX</nasdaq:tickers>
      <nasdaq:tickers>OCR</nasdaq:tickers>
      <nasdaq:tickers>PMC</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/omnicare-unit-partners-drug-buster-analyst-blog-cm249748</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/abco-posts-solid-4q-and-fy2013-earnings-analyst-blog-cm245620">
      <guid isPermaLink="false">245620</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R0OZyLYyJxI/abco-posts-solid-4q-and-fy2013-earnings-analyst-blog-cm245620</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>ABCO Posts Solid 4Q and FY2013 Earnings - Analyst Blog</title>
      <description>The Advisory Board Company  (  ABCO  ) reported fourth quarter fiscal 2013 operating earnings of 33 cents per share surpassing the Zacks Consensus Estimate of 21 cents per share. Results also&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/R0OZyLYyJxI" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 13 May 2013 18:50:01 Z</pubDate>
      <a10:updated>2013-05-13T16:18:31Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ABCO</nasdaq:tickers>
      <nasdaq:tickers>CRL</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>OCR</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/abco-posts-solid-4q-and-fy2013-earnings-analyst-blog-cm245620</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/covance-inc-cvd-todays-most-compelling-stock-buy-cm243860">
      <guid isPermaLink="false">243860</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WI3Yi3lf6Og/covance-inc-cvd-todays-most-compelling-stock-buy-cm243860</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <category>US Markets</category>
      <title>Covance Inc. (CVD): Today's Most Compelling Stock Buy</title>
      <description>           SoTM Bull's Eye Report - Today's Most Compelling Buy       Monday, May 6, 2013          At  StateoftheMarkets.com , we strive to "own the best and ignore the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/WI3Yi3lf6Og" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 06 May 2013 19:48:33 Z</pubDate>
      <a10:updated>2013-05-06T15:48:35Z</a10:updated>
      <author>David Moenning</author>
      <nasdaq:tickers>BIO</nasdaq:tickers>
      <nasdaq:tickers>BRKR</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>PKI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/covance-inc-cvd-todays-most-compelling-stock-buy-cm243860</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/covance-beats-earnings-rev-ups-view-analyst-blog-cm243806">
      <guid isPermaLink="false">243806</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jskF7HmZWM4/covance-beats-earnings-rev-ups-view-analyst-blog-cm243806</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>Covance Beats Earnings, Rev, Ups View - Analyst Blog</title>
      <description>Covance Inc.  (  CVD  ) reported adjusted  earnings per share of 75 cents in the first quarter of 2013,  beating the year-ago results by 25% and the Zacks Consensus  Estimate by 4.2%. &lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/jskF7HmZWM4" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 06 May 2013 17:15:01 Z</pubDate>
      <a10:updated>2013-05-06T13:30:17Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ICLR</nasdaq:tickers>
      <nasdaq:tickers>MDAS</nasdaq:tickers>
      <nasdaq:tickers>OMCL</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/covance-beats-earnings-rev-ups-view-analyst-blog-cm243806</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/covance-augments-singapore-facility-analyst-blog-cm237405">
      <guid isPermaLink="false">237405</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ABK4O43Td_0/covance-augments-singapore-facility-analyst-blog-cm237405</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Covance Augments Singapore Facility - Analyst Blog</title>
      <description>Covance Inc.  (  CVD  ) recently announced that it had completed the expansion of its central laboratory facility in Singapore. Following the expansion of the laboratory by 50%, the company&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ABK4O43Td_0" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 17 Apr 2013 02:40:01 Z</pubDate>
      <a10:updated>2013-04-17T00:14:35Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CPHD</nasdaq:tickers>
      <nasdaq:tickers>CPTS</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>CYBX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/covance-augments-singapore-facility-analyst-blog-cm237405</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/reiterate-healthways-at-neutral-analyst-blog-cm226404">
      <guid isPermaLink="false">226404</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ol73UtVhgvY/reiterate-healthways-at-neutral-analyst-blog-cm226404</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Reiterate Healthways at Neutral - Analyst Blog</title>
      <description>On Mar 7, 2013, we retained  Healthways  (  HWAY  ) at Neutral after the company missed Zacks Consensus Estimate for earnings while reporting in line revenues for fourth quarter 2012.&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ol73UtVhgvY" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 12 Mar 2013 23:28:24 Z</pubDate>
      <a10:updated>2013-03-12T20:12:07Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AIRM</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ESRX</nasdaq:tickers>
      <nasdaq:tickers>HWAY</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/reiterate-healthways-at-neutral-analyst-blog-cm226404</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/longterm-deals-with-drug-makers-help-icons-earnings-cm224097">
      <guid isPermaLink="false">224097</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p2yl3wzr3n0/longterm-deals-with-drug-makers-help-icons-earnings-cm224097</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <title>Long-Term Deals With Drug Makers Help Icon's Earnings</title>
      <description>Publicly traded outsourcing companies have had their share of   success on Wall Street.      No surprise, really, because the value proposition is   compelling. Who doesn't want to save&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/p2yl3wzr3n0" height="1" width="1"/&gt;</description>
      <pubDate>Thu, 07 Mar 2013 00:00:00 Z</pubDate>
      <a10:updated>2013-03-07T12:55:56Z</a10:updated>
      <author>Investor's Business Daily</author>
      <nasdaq:tickers>BMY</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ICLR</nasdaq:tickers>
      <nasdaq:tickers>PFE</nasdaq:tickers>
      <nasdaq:tickers>PRXL</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/longterm-deals-with-drug-makers-help-icons-earnings-cm224097</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/hway-and-wellmont-collaborate-analyst-blog-cm220895">
      <guid isPermaLink="false">220895</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gmDi7G-yIaA/hway-and-wellmont-collaborate-analyst-blog-cm220895</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>HWAY and Wellmont Collaborate - Analyst Blog</title>
      <description>Leading well-being enhancement company  Healthways  (  HWAY  ) and Wellmont Health System recently revealed that their joint efforts in (population) health management resulted in the choice of&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/gmDi7G-yIaA" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 26 Feb 2013 00:20:01 Z</pubDate>
      <a10:updated>2013-02-25T20:34:27Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ACO</nasdaq:tickers>
      <nasdaq:tickers>AIRM</nasdaq:tickers>
      <nasdaq:tickers>CMS</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ESRX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/hway-and-wellmont-collaborate-analyst-blog-cm220895</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/omnicare-tops-est-higher-profit-analyst-blog-cm219231">
      <guid isPermaLink="false">219231</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wtZKdIomluA/omnicare-tops-est-higher-profit-analyst-blog-cm219231</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Omnicare Tops Est., Higher Profit - Analyst Blog</title>
      <description>Provider of drugs to long-term care facilities and nursing homes,  Omnicare Inc.  (  OCR  ) posted fourth-quarter 2012 adjusted (excluding one-time expenses) earnings per share of 86 cents&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/wtZKdIomluA" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 20 Feb 2013 18:30:01 Z</pubDate>
      <a10:updated>2013-02-20T14:52:00Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AIRM</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>OCR</nasdaq:tickers>
      <nasdaq:tickers>PMC</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/omnicare-tops-est-higher-profit-analyst-blog-cm219231</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/esrx-reports-inline-4q-earnings-analyst-blog-cm218999">
      <guid isPermaLink="false">218999</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RotjwTUMYic/esrx-reports-inline-4q-earnings-analyst-blog-cm218999</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Earnings</category>
      <category>Stocks</category>
      <title>ESRX Reports In-Line 4Q Earnings  - Analyst Blog</title>
      <description>Express Scripts Holding Company's  (  ESRX  ) fourth quarter 2012 adjusted earnings of $1.05 per share were in-line with the Zacks Consensus Estimate, and increased 28.1% from the year-ago&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/RotjwTUMYic" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 20 Feb 2013 00:58:01 Z</pubDate>
      <a10:updated>2013-02-19T21:52:19Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ESRX</nasdaq:tickers>
      <nasdaq:tickers>OCR</nasdaq:tickers>
      <nasdaq:tickers>PRXL</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/esrx-reports-inline-4q-earnings-analyst-blog-cm218999</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/mixed-4q-for-charles-river-analyst-blog-cm217896">
      <guid isPermaLink="false">217896</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_cwoLo9svs4/mixed-4q-for-charles-river-analyst-blog-cm217896</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Mixed 4Q for Charles River - Analyst Blog</title>
      <description>Charles River Laboratories  (  CRL  ) reported fourth quarter 2012 earnings (excluding special items) of 64 cents per share, beating the Zacks Consensus Estimate of 60 cents. Earnings declined&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/_cwoLo9svs4" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 15 Feb 2013 01:27:01 Z</pubDate>
      <a10:updated>2013-02-14T21:52:52Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CRL</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>EMD</nasdaq:tickers>
      <nasdaq:tickers>OCR</nasdaq:tickers>
      <nasdaq:tickers>PCS</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/mixed-4q-for-charles-river-analyst-blog-cm217896</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/national-research-corporation-nrci-exdividend-date-scheduled-for-february-14-2013-cm216729">
      <guid isPermaLink="false">216729</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XFYBPdt_EZs/national-research-corporation-nrci-exdividend-date-scheduled-for-february-14-2013-cm216729</link>
      <category>News Headlines</category>
      <category>Stocks</category>
      <title>National Research Corporation (NRCI) Ex-Dividend Date Scheduled for February 14, 2013</title>
      <description>National Research Corporation (  NRCI  ) will begin trading ex-dividend on February 14, 2013. A cash dividend payment of $0.31 per share is scheduled to be paid on March 29, 2013. Shareholders&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/XFYBPdt_EZs" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 12 Feb 2013 19:00:05 Z</pubDate>
      <a10:updated>2013-02-12T14:35:45Z</a10:updated>
      <author>NASDAQ.com News</author>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>INCY</nasdaq:tickers>
      <nasdaq:tickers>NRCI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/national-research-corporation-nrci-exdividend-date-scheduled-for-february-14-2013-cm216729</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/healthways-agrees-with-carondelet-analyst-blog-cm216457">
      <guid isPermaLink="false">216457</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/feh1AxFE6Kk/healthways-agrees-with-carondelet-analyst-blog-cm216457</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Healthways Agrees with Carondelet - Analyst Blog</title>
      <description>Leading well-being enhancement company  Healthways  (  HWAY  ) and Carondelet Health Network recently revealed an agreement to study possibilities in population health management in the Tucson&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/feh1AxFE6Kk" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 12 Feb 2013 01:00:01 Z</pubDate>
      <a10:updated>2013-02-11T21:50:11Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AIRM</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ESRX</nasdaq:tickers>
      <nasdaq:tickers>HWAY</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/healthways-agrees-with-carondelet-analyst-blog-cm216457</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/allfront-easy-beat-for-covance-analyst-blog-cm211321">
      <guid isPermaLink="false">211321</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7lbBFknEJWI/allfront-easy-beat-for-covance-analyst-blog-cm211321</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>All-Front Easy Beat for Covance  - Analyst Blog</title>
      <description>Covance Inc.  (  CVD  ) reported earnings per share (EPS) of 61 cents in the fourth quarter of 2012, higher than the year-ago quarter EPS of 35 cents. The year-over-year increase in earnings&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/7lbBFknEJWI" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 28 Jan 2013 18:40:01 Z</pubDate>
      <a10:updated>2013-01-28T15:26:30Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CPHD</nasdaq:tickers>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>EPS</nasdaq:tickers>
      <nasdaq:tickers>PRXL</nasdaq:tickers>
      <nasdaq:tickers>RMD</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/allfront-easy-beat-for-covance-analyst-blog-cm211321</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/afterhours-earnings-report-for-january-24-2013-msft-t-sbux-ed-jnpr-mxim-klac-jbht-rmd-vrsn-flex-cvd-cm210508">
      <guid isPermaLink="false">210508</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1vWA4Ng9ayQ/afterhours-earnings-report-for-january-24-2013-msft-t-sbux-ed-jnpr-mxim-klac-jbht-rmd-vrsn-flex-cvd-cm210508</link>
      <category>News Headlines</category>
      <category>Earnings</category>
      <title>After-Hours Earnings Report for January 24, 2013 :  MSFT, T, SBUX, ED, JNPR, MXIM, KLAC, JBHT, RMD, VRSN, FLEX, CVD</title>
      <description>The following companies are expected to report earnings after hours on 01/24/2013. Visit our  Earnings Calendar  for a full list of expected earnings releases.   Microsoft Corporation  (  MSFT  )&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/1vWA4Ng9ayQ" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 25 Jan 2013 00:00:04 Z</pubDate>
      <a10:updated>2013-01-24T19:24:31Z</a10:updated>
      <author>NASDAQ.com News</author>
      <nasdaq:tickers>CVD</nasdaq:tickers>
      <nasdaq:tickers>ED</nasdaq:tickers>
      <nasdaq:tickers>FLEX</nasdaq:tickers>
      <nasdaq:tickers>JBHT</nasdaq:tickers>
      <nasdaq:tickers>JNPR</nasdaq:tickers>
      <nasdaq:tickers>KLAC</nasdaq:tickers>
      <nasdaq:tickers>MSFT</nasdaq:tickers>
      <nasdaq:tickers>MXIM</nasdaq:tickers>
      <nasdaq:tickers>RMD</nasdaq:tickers>
      <nasdaq:tickers>SBUX</nasdaq:tickers>
      <nasdaq:tickers>T</nasdaq:tickers>
      <nasdaq:tickers>VRSN</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/afterhours-earnings-report-for-january-24-2013-msft-t-sbux-ed-jnpr-mxim-klac-jbht-rmd-vrsn-flex-cvd-cm210508</feedburner:origLink></item>
  </channel>
</rss>
